[Assessment of therapeutic equivalence of original bisoprolol and its generics in patients with ischemic heart disease with concomitant chronic obstructive pulmonary disease].
Therapeutic equivalence of original bisoprolol (Concor) and its two generics (Biprol and Biol) was studied in 102 patients with ischemic heart disease (IHD) combined with chronic obstructive pulmonary disease (COPD). Concor, Biprol and Biol were given for 12 weeks to 36, 36, and 30 patients, respectively. Methods comprised test with endothelium dependent vasodilation, 24-hour ECG monitoring, pulmonary ventilation tests, and measurement of blood concentrations of nitrous oxide metabolites. Hypotensive and antiischemic effects were similar in all groups. However significant improvement of endothelial function occurred only among Concor treated patients. No negative changes of parameters of pulmonary ventilation took place after 4 weeks of therapy but after 12 weeks their significant lowering was observed among Biprol treated patients. We conclude that in this study on patients with IHD and COPD original bisoprolol demonstrated higher clinical efficacy and better tolerability than its generics.